Introduction
============

Cardiac resynchronization therapy (CRT) has been identified as a well-established treatment protocol for selected patients with progressive heart failure. Responders to this procedure frequently experience reversal of left ventricular (LV) remodeling and thus enhanced systolic function, which contributes to a reduction in hospital admission and improvement in survival.[@b1-jthc-7-10]--[@b5-jthc-7-10] On the other hand, non-responders may represent a consistently high proportion of all recipients of biventricular stimulation (estimated at 25 to 30%), which can be in consequence of inappropriate patient selection or implementation deficiency.[@b6-jthc-7-10] Along with lack of LV dyssynchrony, extensive myocardial scarring, posterolateral transmural infarction, and inappropriate device programming, suboptimal LV lead position is implicated in non-response.[@b6-jthc-7-10]--[@b8-jthc-7-10] It has been recently demonstrated that the correlation between the pacing site and the maximal dyssynchrony site translates into an improved clinical outcome, as well as reduced mortality and heart failure hospitalizations.[@b9-jthc-7-10]

One of the main restricting factors of the LV lead placement is the variability in the coronary venous anatomy. Some previous invasive studies have shown the variation of the coronary anatomy between individual patients, especially in those with a history of ischemic events like myocardial infarction or previous coronary artery bypass grafting surgery (CABG).[@b10-jthc-7-10]--[@b14-jthc-7-10] However, only a few studies have thus far been published on the impact of these pathological differences on the potential for the LV lead targeting. Therefore, based on a hypothesis that the suggested differences in the quantity and distribution of coronary veins between patients with ischemic and non-ischemic cardiomyopathy might affect the potential for the LV lead targeting in patients undergoing CRT, we reviewed the retrograde coronary sinus venograms at the time of CRT implantation to assess the potential for targeted LV lead placement. In other words, we assessed the suitability of the coronary venous system for the LV lead placement in ischemic and dilated cardiomyopathy.

Methods
=======

This single-centre study, conducted at Tehran Heart Center, retrospectively reviewed the retrograde contrast venograms of 173 patients (aged 18--78 years) who underwent CRT device implantation with documented ischemic or dilated cardiomyopathy between March 2003 and March 2010. Past medical history, clinical data, and paraclinical findings, comprising suitability of coronary venouses alongside final LV lead implantation, were assessed. Selection for device implantation was based on the following criteria: New York Heart Association (NYHA) class III or IV symptoms and impaired LV systolic function with a mean ejection fraction less than 35%. In all the study subjects, the devices were implanted in the electrophysiology laboratory under local anesthesia. The study was approved by the Review Board of Tehran University of Medical Sciences.

Retrograde radio-opaque contrast injection was performed to delineate the coronary venous anatomy following coronary sinus intubation. If coronary venography was deemed to have been performed incompletely, an occlusive balloon catheter was inserted into the coronary sinus to maximize coronary venous opacification. The retrograde contrast venograms were prospectively evaluated, and the quantity and distribution of the coronary veins as well as the final lead position were evaluated. The coronary veins were documented for their presence as well as their deemed suitability to receive an LV pacing lead by an experienced cardiologist based upon the vessel caliber, course, and tortuosity.

The results are reported as mean ± standard deviation (SD) for the quantitative variables and percentages for the categorical variables. The groups were compared using the Student t-test for the continuous variables and the chi-square test (or Fisher exact test if required) for the categorical variables. P values ≤ 0.05 were considered statistically significant. All the statistical analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

A total of 173 patients were assessed. The study population included 74 patients with a history of ischemic heart disease, defined as coronary stenoses \> 50% in at least one epicardial artery. Of this group, 43 (58.1%) patients had previously undergone CABG. The baseline characteristics of all the patients according to the underlying etiology are depicted in [Table 1](#t1-jthc-7-10){ref-type="table"}. Except for the male-to-female ratio and mean age, which were higher in the ischemic group, the other baseline characteristics were similar between the two study groups.

Regarding the drugs used, nitrates, statins, and spironolacton were administered more in the ischemic group than in the non-ischemic group. The LV lead positions in the ischemic and non-ischemic patients were as follows: posterior vein (1.6% versus 0.0%); posterolateral vein (11.3% versus 10.3%); lateral vein (75.8% versus 79.5%); anterolateral vein (4.8% versus 7.7%); middle vein (4.8% versus 1.3%); and anterior (1.6% versus 1.3%). There were no significant differences in terms of the distribution of the final LV lead positions between the two groups ([Figure 1](#f1-jthc-7-10){ref-type="fig"}).

[Tables 2](#t2-jthc-7-10){ref-type="table"} and [3](#t3-jthc-7-10){ref-type="table"} illustrate the quantity and distribution of the coronary veins identified and the proportion of the veins deemed suitable targets for potential LV lead placement. Twenty-three (31.1%) patients in the ischemic group and 24 (24.2%) in the dilated group had only one suitable vein. The most available suitable vein in both groups was the lateralvein, followed by the posterior vein in the ischemic and the posterolateral vein in the dilated group. There was no significant difference between the two groups with respect to the position of the available suitable vein with the exception of the posterior position, in which the ischemic group had slightly more suitable veins than did the dilated group. Nevertheless, there was no significant difference as regards the final vein through which the LV lead was inserted.

The results were also considered in the two subgroups of ischemic patients with and without a history of CABG ([Table 4](#t4-jthc-7-10){ref-type="table"}). Comparative analysis showed that the patients with pre-CABG had significantly fewer suitable veins in the posterolateral position than did the others; there was, however, no significant difference between the two subgroups regarding the final vein position through which the leads were inserted.

Discussion
==========

The present study is a report on the quantity and distribution of the coronary venous anatomy for the LV lead targeting in patients undergoing CRT. We hypothesized that the main etiology of heart failure might affect the quality of the lead targeting and showed that the underlying ischemic or nonischemic etiologies of heart failure did not appear to make significant differences in the potential for the ventricular lead targeting.

Newly designed pacemakers along with developments in lead implantation techniques such as trans-coronary venous lead insertion have thoroughly revolutionized CRT and management of cardiomyopathy diseases. The LV lead placement is restricted by the variability in the coronary venous anatomy. In addition, there may be issues related to the lead instability, inadequate pacing and sensing thresholds, and diaphragmatic pacing. In this context, the LV lead position has emerged as an important determinant of response. Even small changes in the LV lead position may be associated with exquisite changes in acute myocardial performance.[@b15-jthc-7-10]

On the basis of our findings and the abovementioned points, the general approach at present is to place the LV lead in the lateral region, which has been previously reported.[@b16-jthc-7-10] In a similar study by Zaman Khan et al.,[@b6-jthc-7-10] the underlying etiology could not affect the quantity and distribution of the coronary veins available for the ventricular lead placement.

With respect to the influence of the ischemic etiology of heart failure, we observed no significant differences between the two subgroups with and without a history of CABG regarding the final vein position through which the leads were inserted. In addition, in our research, the patients with pre-CABG had significantly fewer suitable veins in only the posterolateral position. However, differences between groups of patients have been suggested by some authors who reported a paucity of lateral veins in subgroups of patients with either a history of myocardial infarction or previous CABG.[@b17-jthc-7-10], [@b18-jthc-7-10] In light of the fact that some previous studies using MDCT have shown that variations in the coronary venous anatomy are consistent with a prior history of MI or CABG, our finding is slightly unexpected.

Conclusion
==========

The results of our study demonstrated that the final coronary vein position suitable and selected for the LV lead insertion was not different between the cases with cardiomyopathy with different etiologies, and nor was it different between the ischemic cases with and without a history of CABG. In other words, patients with a history of procedures around the coronary vessel may have an intact or recovered venous system and may, as a result, benefit from the transvenous LV lead placement for CRT.
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###### 

Baseline characteristics of all patients[^\*^](#tfn1-jthc-7-10){ref-type="table-fn"}

  Characteristics           Ischemic group (n=74)   Non-ischemic group (n=99)   P value
  ------------------------- ----------------------- --------------------------- ----------
  Male gender               63 (85.1)               55 (55.6)                   \< 0.001
  Age (yr)                  60.7±7.7                53.1±14.7                   \< 0.001
  Diabetes mellitus         49 (66.2)               74 (74.7)                   0.221
  Hypertension              60 (81.1)               80 (80.8)                   0.964
  NYHA score                                                                    0.409
    III                     53 (71.6)               64 (64.6)                   
    IV                      21 (28.4)               35 (35.4)                   
  Valvular\\heart disease   8 (10.8)                13 (13.1)                   0.644
  QRS (ms)                  148.2±34.9              144.8±23.9                  0.455
  EF (%)                    21.9±8.7                20.7±5.4                    0.318
  LVESV (mL)                169.2±77.5              154.9±81.7                  0.320
  LVEDV (mL)                212.4±81.7              200.3±96.1                  0.450
  Medication                                                                    
    Digoxin                 56 (75.7)               82 (82.8)                   0.247
    Carvedilol              44 (59.5)               52 (52.5)                   0.364
    Nitrate                 51 (68.9)               35 (35.4)                   \< 0.001
    Beta-blocker            7 (9.5)                 13 (13.1)                   0.455
    Anti-arrhythmia         23 (31.1)               31 (31.3)                   0.974
    Warfarin                5 (6.8)                 10 (10.1)                   0.439
    Calcium-blocker         3 (4.1)                 4 (4.0)                     0.999
    Statin                  45 (60.8)               32 (32.3)                   \< 0.001
    Diuretic                55 (74.3)               76 (76.8)                   0.711
    ACE-inhibitor           46 (62.2)               53 (53.5)                   0.257
    Spironolactone          35 (47.3)               63 (63.6)                   0.032

Data are presented as mean±SD or number (%)

NYHA, New York Heart Association; EF, Ejection fraction; LVESV, Left ventricular end systolic volume; LVEDV, Left ventricular end diastolic volume; ACE, Angiotensin converting enzyme

###### 

Characteristics of suitable veins in all patients and subgroups according to underlying etiology[^\*^](#tfn3-jthc-7-10){ref-type="table-fn"}

  Vein             Total        Ischemic group   Non-ischemic group   P value
  ---------------- ------------ ---------------- -------------------- ---------
  Lateral          117 (83.6)   50 (80.6)        67 (85.9)            0.405
  Posterior        55 (39.3)    30 (48.4)        25 (32.1)            0.049
  Posterolateral   47 (33.6)    18 (29.0)        29 (37.2)            0.311
  Anterolateral    42 (30.0)    17 (27.4)        25 (32.1)            0.552
  Middle           14 (10.0)    7 (11.3)         7 (9.0)              0.650

Data are presented as number (%)

###### 

Number of suitable veins in all patients and subgroups according to underlying etiology[^\*^](#tfn4-jthc-7-10){ref-type="table-fn"}

  Vein    Total       Ischemic group   Non-ischemic group   P value
  ------- ----------- ---------------- -------------------- ---------
  None    25 (14.5)   7 (9.5)          18 (18.2)            0.160
  One     47 (27.2)   23 (31.1)        24 (24.2)            0.451
  Two     73 (42.2)   32 (43.2)        41 (41.4)            0.878
  Three   22 (12.7)   8 (10.8)         14 (14.1)            0.566
  Four    6 (3.5)     4 (5.4)          2 (2.0)              0.246

Data are presented as number (%)

###### 

Characteristic of suitable veins in ischemic group according to the history of coronary artery bypass surgery (CABG)[^\*^](#tfn5-jthc-7-10){ref-type="table-fn"}

  Vein             CABG group   Non-CABG group   P value
  ---------------- ------------ ---------------- ---------
  Lateral          32 (74.4)    19 (61.3)        0.229
  Posterior        20 (46.5)    13 (41.9)        0.696
  Posterolateral   7 (16.3)     12 (38.7)        0.029
  Anterolateral    7 (16.3)     10 (32.3)        0.107
  Middle           4 (9.3)      3 (9.7)          0.957

Data are presented as number (%)
